In The Scientist’s Innovation Spotlight Q&A, our CEO Andrea Choe reveals how Holoclara is pioneering a new frontier in drug discovery by harnessing nature’s symbiotic species, starting with molecules derived from worms. 🪱💊

Read the full feature 👇
www.the-scientist.com/turning-worm...

Today we recognize the 1st World Eosinophilic Esophagitis (EoE) Day!

We’re raising awareness and reaffirming our commitment to pioneering treatments for underserved patients through the therapeutic potential of worms! 🪱

Learn more: www.holoclara.com

#NEAW #EosAware

On AUTM on the Air, our CEO Andrea Choe shared insights on Holoclara’s work harnessing worm-derived molecules for medicine, along with her experiences collaborating with tech transfer offices at @caltech.edu and @cornelluniversity.bsky.social.

🎧 Listen now: www.youtube.com/watch?v=TZIy...

Worms were long overlooked—now they could help transform human health. 🪱

Our CEO Andrea Choe, shared the science behind our discovery engine and its potential to access other untapped sources with In Vivo Citeline.

Read more 👇
tinyurl.com/4vr8sp96

How might the “dark matter” of biology unlock new medicines? 🌌

Labiotech’s must-read explainer covers the rise of metabolomics as a critical tool for decoding biology, featuring insights from our CEO Andrea Choe.

Check it out 👇 www.labiotech.eu/in-depth/met...

In an @asbmb.bsky.social interview, CEO Andrea Choe shared how treating patients inspired her shift from medicine to entrepreneurship, founding Holoclara to bring relief to millions suffering from debilitating diseases – by harnessing molecules from worms. 🪱
Read more 👇
www.asbmb.org/asbmb-today/...

Great to be featured in Labiotech’s Best in Biotech series! Check out their article to learn how we’re decoding biology through metabolomics to pioneer worm-derived therapies: www.labiotech.eu/best-biotech...

Great to see our CEO Andrea Choe on stage at Caltech's Merkin Institute Symposium where she shared insights from founding Holoclara amongst fellow entrepreneurs, scientists, and leaders.💡

🎧On the latest @InVivoPodOnX episode, our CEO Andrea Choe discussed the incredible therapeutic potential of gut-dwelling roundworms and Holoclara's work harnessing worm-derived molecules to treat devastating disorders.

Tune in now 👇
youtu.be/dJluLzQ67K4?...

We’re pleased to announce our first-in-human Phase 1 clinical trial of HC002 – a novel worm-derived medicine – and eosinophilic esophagitis (EoE) as our lead indication.

Check out our video and press releases below for more on HC002 and EoE ⬇️